HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd

Christian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, Ulrike Maria Heber, Charlotte Mang‐Manger, Daniel Egle, Marija Balic, Angelika Pichler, Georg Pfeiler, Stephanie Kacerovsky‐Strobl, Christoph Suppan, Magdalena Ritter, Edgar Petru, Richard Greil, Zsuzsanna Bago‐Horvath, Christine Deutschmann, Günther Georg Steger, Michael Seifert, Florian Fitzal, Rupert Bartsch, Anu Santhanagopal, Jana Machacek‐Link, Dalila Sellami, Magdalena Schwarz, Christian Fesl, Lidija Sölkner, Stephen Esker, Martin Filipits, Michael Gnant, Unknown

Open source

DOI
10.1002/cac2.12657
Published
2025-01-06
Container
Cancer Communications
Publisher
American Association for the Advancement of Science (AAAS)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cac2.12657,
  title = {HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd},
  author = {Christian Fridolin Singer and Stephan Wenzel Jahn and Dominik Hlauschek and Ulrike Maria Heber and Charlotte Mang‐Manger and Daniel Egle and Marija Balic and Angelika Pichler and Georg Pfeiler and Stephanie Kacerovsky‐Strobl and Christoph Suppan and Magdalena Ritter and Edgar Petru and Richard Greil and Zsuzsanna Bago‐Horvath and Christine Deutschmann and Günther Georg Steger and Michael Seifert and Florian Fitzal and Rupert Bartsch and Anu Santhanagopal and Jana Machacek‐Link and Dalila Sellami and Magdalena Schwarz and Christian Fesl and Lidija Sölkner and Stephen Esker and Martin Filipits and Michael Gnant and Unknown},
  year = {2025},
  journal = {Cancer Communications},
  doi = {10.1002/cac2.12657},
  url = {https://doi.org/10.1002/cac2.12657}
}

RIS

TY  - JOUR
TI  - HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd
AU  - Christian Fridolin Singer
AU  - Stephan Wenzel Jahn
AU  - Dominik Hlauschek
AU  - Ulrike Maria Heber
AU  - Charlotte Mang‐Manger
AU  - Daniel Egle
AU  - Marija Balic
AU  - Angelika Pichler
AU  - Georg Pfeiler
AU  - Stephanie Kacerovsky‐Strobl
AU  - Christoph Suppan
AU  - Magdalena Ritter
AU  - Edgar Petru
AU  - Richard Greil
AU  - Zsuzsanna Bago‐Horvath
AU  - Christine Deutschmann
AU  - Günther Georg Steger
AU  - Michael Seifert
AU  - Florian Fitzal
AU  - Rupert Bartsch
AU  - Anu Santhanagopal
AU  - Jana Machacek‐Link
AU  - Dalila Sellami
AU  - Magdalena Schwarz
AU  - Christian Fesl
AU  - Lidija Sölkner
AU  - Stephen Esker
AU  - Martin Filipits
AU  - Michael Gnant
AU  - Unknown
PY  - 2025
JO  - Cancer Communications
DO  - 10.1002/cac2.12657
UR  - https://doi.org/10.1002/cac2.12657
ER  - 

APA

Singer, C. F., Jahn, S. W., Hlauschek, D., Heber, U. M., Mang‐Manger, C., Egle, D., Balic, M., Pichler, A., Pfeiler, G., Kacerovsky‐Strobl, S., Suppan, C., Ritter, M., Petru, E., Greil, R., Bago‐Horvath, Z., Deutschmann, C., Steger, G. G., Seifert, M., Fitzal, F., Bartsch, R., Santhanagopal, A., Machacek‐Link, J., Sellami, D., Schwarz, M., Fesl, C., Sölkner, L., Esker, S., Filipits, M., Gnant, M., & Unknown (2025). HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd. Cancer Communications. https://doi.org/10.1002/cac2.12657

Source records